Endevica Bio Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Endevica Bio General Information

Description

Developer of therapeutic drugs intended to treat cachexia caused by cancer and other chronic conditions. The company's drugs are melanocortin-based peptides for treating cardiovascular problems, which are free from any adverse cardiovascular side effects, enabling healthcare practitioners to reverse cachexia and improve quality of life in cancer patients.

Contact Information

Formerly Known As
Tensive Controls
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1935 Techny Road
  • Suite 14
  • Northbrook, IL 60062
  • United States
+1 (573)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1935 Techny Road
  • Suite 14
  • Northbrook, IL 60062
  • United States
+1 (573)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endevica Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 19-Jan-2023 Completed Startup
2. Grant 01-Jun-2017 $4.57M $1.7M Completed Startup
1. Later Stage VC (Series A) 01-Jun-2016 $1.7M $1.7M Completed Startup
To view Endevica Bio’s complete valuation and funding history, request access »

Endevica Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Endevica Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Endevica Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endevica Bio Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Cancer Institute Government
Centennial Investors Angel Group Minority
NIH Office of the Director Government Minority
To view Endevica Bio’s complete investors history, request access »

Endevica Bio FAQs

  • When was Endevica Bio founded?

    Endevica Bio was founded in 2009.

  • Where is Endevica Bio headquartered?

    Endevica Bio is headquartered in Northbrook, IL.

  • What is the size of Endevica Bio?

    Endevica Bio has 23 total employees.

  • What industry is Endevica Bio in?

    Endevica Bio’s primary industry is Drug Discovery.

  • Is Endevica Bio a private or public company?

    Endevica Bio is a Private company.

  • What is Endevica Bio’s current revenue?

    The current revenue for Endevica Bio is .

  • How much funding has Endevica Bio raised over time?

    Endevica Bio has raised $11.7M.

  • Who are Endevica Bio’s investors?

    National Cancer Institute, Centennial Investors, and NIH Office of the Director have invested in Endevica Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process